FDA interested in details of industry OTC anticaries biological testing plan -- Bowen.
This article was originally published in The Tan Sheet
Executive Summary
FDA INTERESTED IN DETAILED INDUSTRY PLAN FOR ANTICARIES BIOLOGICAL TESTING as the agency considers industry's request to postpone the Oct. 7 effective date of the anticaries final monograph by one year. OTC Division Director Debra Bowen expressed interest in the information at an April 3 OTC "feedback" meeting with the oral care task force, formed jointly by the Nonprescription Drug Manufacturers Association and the Cosmetic, Toiletry and Fragrance Association.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning